Literature DB >> 23849028

What do we know about the outcomes of tuberculosis contact investigations in NSW?

Claudia C Dobler1.   

Abstract

A recently conducted study on tuberculosis contact investigations in six Sydney tuberculosis clinics - that together managed 59% of all tuberculosis cases in NSW from January 2000 to December 2009 - found that the prevalence of tuberculosis among contacts was comparable to other low-incidence settings. However, only 9% of contacts with latent tuberculosis infection received treatment. This paper explores the results of the study, evaluating potential missed opportunities to prevent tuberculosis among contacts, and discussing the mechanisms in decision making about treatment of latent tuberculosis infection. In particular, the paper focuses on the challenges of tuberculin skin test interpretation among contacts who have received Bacille Calmette-Guérin vaccination and who were born in countries where tuberculosis is endemic.

Entities:  

Mesh:

Year:  2013        PMID: 23849028     DOI: 10.1071/NB12099

Source DB:  PubMed          Journal:  N S W Public Health Bull        ISSN: 1034-7674


  4 in total

1.  Evaluation of tuberculin skin testing in tuberculosis contacts in Victoria, Australia, 2005-2013.

Authors:  N Moyo; E L Tay; J T Denholm
Journal:  Public Health Action       Date:  2015-09-21

2.  Attitudes towards preventive tuberculosis treatment among hospital staff.

Authors:  Vidya Pathak; Zinta Harrington; Claudia C Dobler
Journal:  PeerJ       Date:  2016-02-25       Impact factor: 2.984

3.  Physicians' perspectives on communication and decision making in clinical encounters for treatment of latent tuberculosis infection.

Authors:  Claudia C Dobler; Sinthia Bosnic-Anticevich; Carol L Armour
Journal:  ERJ Open Res       Date:  2018-03-23

4.  What patient factors predict physicians' decision not to treat latent tuberculosis infection in tuberculosis contacts?

Authors:  Claudia C Dobler; Queenie Luu; Guy B Marks
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.